go-v.orgdoi

Association of Smoking Status with Efficacy of First-line Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancers: A Systematic Review and Meta-analysis

Jinchul Kim, Hyerim Ha, Jisun Park, Jinhyun Cho, Joo Han Lim, Moon Hee Lee · Journal of Cancer · 2021

  • DOI 10.7150/jca.65374
  • Publisher Ivyspring International Publisher
  • Type review
  • Issued 2021

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · review · 2021

Abstract

Background: Although smoking status has potential as a biomarker for immune checkpoint blockade in advanced non-small cell lung cancer (NSCLC), its clinical significance remains obscure.This meta-analysis aims to assess the impact of the smoking status on the efficacy of first-line immunotherapy and to find better treatment in never-smoker and ever-smoker patients.Methods: We searched the MEDLINE, EMBASE, and Cochrane database for trials comparing immunotherapy with conventional chemotherapy as front-line treatment for advanced NSCLC.Random-effects models were used to pool estimates of hazard ratios (HRs) for overall survival with 95% confidence intervals (CIs).Predefined subgroup analysis was performed to investigate the difference in the efficacy between the single checkpoint blockade and checkpoint inhibitor plus chemotherapy combination in the never-smokers and current/former smokers.Results: Twelve trials involving 6,446 patients were included in the analysis.A statistically significant overall survival benefit over conventional chemotherapy was found for both checkpoint inhibitor monotherapy (HR, 0.71; 95% CI, 0.59-0.85)and checkpoint inhibitor plus chemotherapy (HR, 0.75; 95% CI, 0.63-0.90) in the current/former smoker group.There was no subgroup difference between monotherapy and combination treatment (p=0.67).However, there was an inconsistent survival outcome in the never-smoker group; checkpoint blockade monotherapy did not show significantly better efficacy than chemotherapy alone (HR, 1.05; 95% CI, 0.81-1.37),but combination treatment showed an overall survival benefit (HR, 0.64; 95% CI, 0.43-0.94).A significant subgroup difference existed between monotherapy and combination therapy (p=0.04).Similarly, there was a significant difference in efficacy of monotherapy between the current/former smoker and never-smoker group (p=0.01),but the efficacy of the combination treatment was comparable between the two groups (p=0.45).Conclusion: Smoking status, which is easily available information, could be used as a guide in clinical practice to choose better treatment in the front-line setting for advanced NSCLC patients.

Open the resolved locator · 10.7150/jca.65374

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 21:15 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v13p0364.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.